Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors - PubMed (original) (raw)
doi: 10.1002/hon.976. Epub 2010 Oct 27.
- PMID: 21922510
- DOI: 10.1002/hon.976
Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors
Daniel A Pollyea et al. Hematol Oncol. 2011 Sep.
No abstract available
Similar articles
- Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, Przychodzen B, Mian SA, Nasser EE, Shooter C, Westwood NB, Strupp C, Gattermann N, Maciejewski JP, Germing U, Mufti GJ. Smith AE, et al. Blood. 2010 Nov 11;116(19):3923-32. doi: 10.1182/blood-2010-03-274704. Epub 2010 Aug 6. Blood. 2010. PMID: 20693430 - Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
Liu X, Zhang G, Yi Y, Xiao L, Pei M, Liu S, Luo Y, Zhong H, Xu Y, Zheng W, Shen J. Liu X, et al. Leuk Lymphoma. 2013 Nov;54(11):2466-73. doi: 10.3109/10428194.2013.778408. Epub 2013 Mar 27. Leuk Lymphoma. 2013. PMID: 23432690 - TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Yun J, Ji YS, Jang GH, Lim SH, Kim SH, Kim CK, Bae SB, Won JH, Park SK. Yun J, et al. Curr Issues Mol Biol. 2021 Aug 5;43(2):917-931. doi: 10.3390/cimb43020065. Curr Issues Mol Biol. 2021. PMID: 34449560 Free PMC article. - Interpreting new molecular genetics in myelodysplastic syndromes.
Abdel-Wahab O, Figueroa ME. Abdel-Wahab O, et al. Hematology Am Soc Hematol Educ Program. 2012;2012:56-64. doi: 10.1182/asheducation-2012.1.56. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233561 Review. - [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
Wang JY, Xiao ZJ. Wang JY, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1303-9. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011. PMID: 22040993 Review. Chinese.
Cited by
- Mutations in epigenetic regulators in myelodysplastic syndromes.
Nikoloski G, van der Reijden BA, Jansen JH. Nikoloski G, et al. Int J Hematol. 2012 Jan;95(1):8-16. doi: 10.1007/s12185-011-0996-3. Epub 2012 Jan 11. Int J Hematol. 2012. PMID: 22234528 Review. - Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations.
Jiang Y, Eveillard JR, Couturier MA, Soubise B, Chen JM, Gao S, Basinko A, Morel F, Douet-Guilbert N, Troadec MB. Jiang Y, et al. Cancers (Basel). 2021 Jan 27;13(3):481. doi: 10.3390/cancers13030481. Cancers (Basel). 2021. PMID: 33513838 Free PMC article. - The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. Solary E, et al. Leukemia. 2014 Mar;28(3):485-96. doi: 10.1038/leu.2013.337. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220273 Review. - Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies.
Czegle I, Gray AL, Wang M, Liu Y, Wang J, Wappler-Guzzetta EA. Czegle I, et al. Life (Basel). 2021 Dec 7;11(12):1351. doi: 10.3390/life11121351. Life (Basel). 2021. PMID: 34947882 Free PMC article. Review. - Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.
Fathi AT, Abdel-Wahab O. Fathi AT, et al. Adv Hematol. 2012;2012:469592. doi: 10.1155/2012/469592. Epub 2011 Jun 26. Adv Hematol. 2012. PMID: 21811504 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous